目的 探讨18F-PET/CT显像在甲 状腺癌失分化患者定期复查中的应用价 值。方法 收集我院2012年1月至2016年 6月收治的行18F-FDG PET/CT检查的分化 型甲状腺癌患者45例作为研究对象展开 回顾性分析，以手术/随访结果为基准， 计算18F-FDG PET/CT的敏感性与阳性预 测值。结果 45例患者中，18F-FDG PET/ CT检查示42例患者为阳性显像，敏感性 为93.3%(42/45)。45例患者共发现105个 颈部转移淋巴结、9例肺转移、6枚纵隔 淋巴结，术后病理证实111个为肿瘤复发 或转移、9例为炎性病灶，阳性预测值 为92.5%(111/120)。结论 18F-FDG PET/ CT显像在术后大剂量131I治疗后Tg升高 而131I-全身扫描结果显示为阴性的失分 化甲状腺癌患者中的应用，可通过对肿 瘤代谢状态的观察有效避免漏诊，以定 期复查方式尽早发现患者复发或转移病 灶，并为后续治疗提供指导，具有显著 临床应用价值

Objective To explore the application value of 18F-PET/CT imaging in periodic reviews in patients with thyroid carcinoma differentiation. Methods 45 patients with thyroid carcinoma differentiation who underwent 18F-FDG PET/CT examination in our hospital from January 2012 to June 2016 were enrolled in the study to carry out retrospective analysis, operation/follow up results were called a baseline, sensitivity and positive predictive value of 18F-FDG PET/CT were calculated. Results 18F-FDG PET/ CT examination found that 42 patients were positive imaging in 45 patients, sensibility was 93.3% (42/45). 105 cases of cervical lymph node metastasis, 9 cases of pulmonary lymph nodes, 6 cases of mediastinal lymph nodes were found in 45 patients, postoperative pathologic confirmed that 111 cases were tumor recurrence or metastasis, 9 cases were inflammatory disease, positive predictive value was 92.5%(111/120). Conclusion 18FFDG PET/CT imaging after postoperative large dose 131I treatment, Tg is increased, 131I-body scan results show that negative patients with thyroid carcinoma differentiation can avoid missed diagnosis effectively by the observation of tumor metabolism, periodic reviews can find out recurrence or metastatic lesions as soon as possible, and provide guidance for follow-up treatment, has significant clinical application value.